Normal Amsler Grid appearance.
Normal Amsler Grid appearance.

Normal Amsler Grid appearance.

Appearance of Amsler grid with macular disease. Note distorted image.

Appearance of Amsler grid with macular disease.
Note distorted image.

Normal Amsler Grid appearance.

Appearance of Amsler grid with wet AMD.
Note distortion and darkened spot.

Age-related macular degeneration (AMD) is the most common cause of vision loss in persons over 50 years of age world-wide. Millions are affected, and because it is an aging change, AMD is becoming increasingly common as the world population ages.

“Dry” AMD is the earliest stage, and affects everyone with AMD. Most people with dry AMD have good vision on the eye chart, but have increasing difficulty at night and indoors, needing more light and higher contrast (black and white rather than shades of grey) to see well. Severe visual loss with dry AMD is uncommon, and usually occurs when a condition called “geographic atrophy” develops.

“The other day I realized that I was reading the scores at the bottom of the TV screen again. I couldn’t do that before the laser treatment. And the distortion and waviness was gone.” 76 year old woman with dry AMD.

“Wet” AMD is the most common reason people with dry AMD lose vision. This happens when an eye with dry AMD develops scar tissue growth under the center of the retina (called the macula), causing damage that destroys the macula and central, sharp vision. Without macular vision, your ability to read, recognize faces, and drive may be lost.

gen-group

Vision Protection Therapy™ (VPT™)

The first effective preventive treatment for AMD 

Featured in the October 13, 2020 edition of the online medical magazine Medscape

 

Most people with dry AMD keep good vision unless they develop wet AMD. However, some with dry AMD experience rapid and severe loss of central vision due to “wearing out” of the macula, called “geographic atrophy” (GA). Until recently, there has been no treatment for GA. However, VPT™can reduce the rate of GA progression by 47% per year compared to AREDS vitamins alone. VPT does this safely, while also improving indoor vision and reducing the risk of developing wet AMD. VPT™ is the only treatment to safely slow progression of AMD, even in the most severe form of dry AMD – geographic atrophy.

If you have “wet” AMD, VPT™ can help in several important ways. As you know, drugs injected into the eye are the primary treatment for wet AMD. VPT™ helps these drugs work better. What does this mean? Injections can be significantly reduced without sacrificing visual results.  By decreasing the number of injections, VPT™ can reduce the risks of vision-threatening complications of injections, such as macular atrophy, infection and glaucoma. 

Vision Protection Therapy™ (VPT™) can reduce your risk of developing “wet” AMD.  The Age-Related Eye Disease Study (AREDS) showed that vitamins can reduce the risk of visual loss in dry AMD by about 4% per year. Recent studies demonstrate that VPT™ can reduce your risk of developing wet AMD by over 90% per year even if you take AREDS vitamins.  At the same time, VPT™ improves indoor vision, making it easier to read and watch TV.  

Real World Data.  High Quality Data. An in-depth analysis of VPT™ for AMD, using a national database of over 300 US retina specialists and over 300,000 AMD patients (Vestrum Health) throughout the US was done, to compare patients who did, or did not, receive VPT™  treatment for AMD. Using a statistical method called “propensity scoring” to obtain the highest quality patient and risk-factor matching, VPT™ was found to markedly reduce the development of wet AMD compared to standard care without SDM. Eyes with dry AMD receiving VPT™ were over 1,300% less likely to develop wet AMD and vision loss than patients who only took AREDS vitamins (see graph below). Eyes receiving VPT™ had better vision that patients using AREDS vitamins alone, by an average of 9 letters (2 lines) on the eye chart. In eyes with wet AMD, VPT™ reduced the need eye injections by 69% compared to standard care without VPT™, with the same visual results. 

To review this peer-reviewed study, click on the link below:

https://www.researchgate.net/publication/349952308_Prevention_of_neovascular_AMD_Real_world_efficacy_of_program_of_panmacular_laser_for_vision_protection

The graph above shows the frequency of dry AMD becoming wet (and needing eye injections) over time. The top line shows the rate of new wet AMD using AREDS vitamins alone (SC-National). The bottom line shows rate of new wet AMD with VPT™ (SC+SDM). Note the much lower risk of wet AMD and visual loss in patients getting VPT™. (Study of 9,130 patients from across the U.S. matched by propensity scoring. p<0.0001; Hazard ratio = 13.04)

The Bottom Line: VPT™ is the first and only treatment for AMD to provide each and every one of these critical sight-saving benefits over 1,300% better than AREDS vitamins alone:

Prevent wet AMD

Prevent eye injections

Improve visual acuity

Slow progression of geographic atrophy and dry AMD

Reduce the need for eye injections in wet AMD

Reduce the risk of vision loss from all causes in AMD

There is no drug or any other treatment that can do any of these things, let alone all of these things; and VPT™ does them extraordinarily well. So well, in fact, that it will be very difficult for any future treatment to ever be as safe and effective as VPT™ is, right now.

Studies have shown that the effects of VPT™ in AMD tend to wear off and return to pre-treatment levels about 6-9 months after treatment. Therefore, to maintain maximum treatment benefits to minimize your risks of vision loss from AMD, patients with AMD should repeat VPT™ every 3-4 months.  

Normal retinal appearance

Mesopic (real life) visual fields of eye with dry AMD (AREDS cat 3): left side, before; right side, after, Vision Protection Therapy.
Note poor visual function before treatment, and marked improvement after VPT™.

Mesopic (real life) visual fields of patient with dry AMD (AREDS cat 3): left side, before; right side, after Retinal Protective Therapy. Note improvement in visual function after RPT

Mesopic (real life) visual fields of patient with dry AMD (AREDS cat 3): left side, before; right side, after Vision Protection Therapy.
Note improvement in visual function after VPT™

Multifocal electroretinogram of patient with dry AMD, AREDS Category 3. Top = before RPT. Bottom = after RPT. Note marked improvement in retinal function (health) after RPT.

Multifocal electroretinogram of patient with dry AMD, AREDS Category 3. Top = before RPT. Bottom = after VPT.
Note marked improvement in retinal function (health) after VPT.

Normal retinal appearance

Normal retinal appearance

Dry age-related macular degeneration. High-risk for vision loss.

Dry age-related macular degeneration.
Note yellow area of “worn out”
retina in the macula (geographic atrophy, GA). SDM VPT™ is the only treatment to safely slow progression and reduce the risk of visual loss from GA

Dry age-related macular degeneration. Note yellow area of “worn out” retina in the macula (geographic atrophy).

Dry age-related macular degeneration.
High-risk for vision loss.

Wet age-related macular degeneration. Note bleeding in the macula.

Wet age-related macular degeneration.
Note bleeding in the macula.